SLC5A2 and diabetes mellitus: Therefore, the modulation of the intestinal microbiota combined with other established therapies for DM, including lifestyle modifications, pharmacological drugs including metformin [42,43], sodium-glucose cotransporter-2 inhibitors (SGLT2i) [44,45], GLP-1 receptor agonists [46,47], and lipid-lowering drugs, such as statins [48,49], can result in better metabolic parameters, which may ultimately mitigate the damage associated with this complex pathophysiology.